Skip to main content

Table 1 Patient characteristics

From: Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission

Patient Gender Age
(years)
FAB Karyotype Molecular mutations
      FLT3-ITD MLL-PTD NPM1
# 1 M 64 M2 46, XY - - +
# 2 M 71 M4 46, XY + - +
# 3 M 45 M3v 46, XY, t(15;17) - - -
# 4 F 70 M1 46, XX - - -
# 5 M 69 M4 46, XY - - +
# 6 F 23 M2 46, XX + - +
# 7 M 36 M3 46, XY, t(15;17) - - -
# 8 F 34 M3 46, XX, t(15;17) - - -
# 9 M 51 M3 46, XY, t(15;17) - - -
# 10 F 39 M2 46, XX - - -
# 11 M 48 M2 46, XY - - -
# 12 M 62 M4 46, XY +(1) - +
# 13 M 37 M3v 46, XY, t(15;17) + - -
# 14 M 63 M4 46, XY - - -
# 15 M 72 M2 45, X, (-Y) + - +
# 16 F 70 M2 46, XX, t(8;21) - - -
# 17 F 32 M5a 46, XX - - -
# 18 M 55 M4 46, XY + - +
# 19 M 67 M0 51, XY, +9, +10, +11, +13 × 2, +3, - - -
# 20 F 28 sAML 46, XY - - +
  1. Abbreviations: M, male; F, female; FAB, French-American-British classification system
  2. (1) AML #12 = FLT3-TKD mutation